Incyte Corp. diskutieren

Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $83.00 price target on the stock, down previously from $84.00.

Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at TD Cowen from $88.00 to $80.00. They now have a "buy" rating on the stock.

Incyte Co. (NASDAQ: INCY) had its "underperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, down previously from $52.00.

Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $84.00 to $81.00. They now have an "outperform" rating on the stock.

Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Citigroup Inc. from $80.00 to $88.00. They now have a "buy" rating on the stock.

Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Guggenheim from $86.00 to $92.00. They now have a "buy" rating on the stock.

Incyte Co. (NASDAQ: INCY) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $84.00 price target on the stock.

Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $90.00 price target on the stock, up previously from $68.00.

Incyte Co. (NASDAQ: INCY) had its "underperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $52.00 price target on the stock, up previously from $48.00.

Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Oppenheimer Holdings Inc. from $81.00 to $82.00. They now have an "outperform" rating on the stock.

Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Citigroup Inc. from $92.00 to $97.00. They now have a "buy" rating on the stock.

Incyte Co. (NASDAQ: INCY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Incyte Co. (NASDAQ: INCY) had its "outperform" rating re-affirmed by analysts at William Blair.

Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Citigroup Inc. from $97.00 to $88.00. They now have a "buy" rating on the stock.

Incyte looks poised for growth despite some near-term headwinds. Their flagship drug Jakafi continues to see solid demand, especially in polycythemia vera. The dermatology franchise led by Opzelura is ramping up nicely. With multiple potential product launches and key data readouts in 2025, Incyte has several catalysts ahead that could drive the stock higher. While Q4 earnings missed expectations, revenues beat and 2025 guidance looks decent. The rich pipeline, including promising programs in myelofibrosis and hidradenitis suppurativa, provides multiple shots on goal. At current levels, the risk/reward seems favorable for this innovative biopharma company.

Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Citigroup Inc..

Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $107.00 price target on the stock.

Incyte Corporation (NASDAQ: INCY) had its price target raised by analysts at Citigroup Inc. from $88.00 to $103.00. They now have a "buy" rating on the stock.

Incyte Corporation (NASDAQ: INCY) had its price target raised by analysts at BMO Capital Markets from $52.00 to $60.00. They now have an "underperform" rating on the stock.